Targanta Files Oritavancin NDA For cSSSI, Aiming To Tackle Vancomycin Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Third owner of Lilly-developed compound touts antibiotic’s shorter course of treatment and dosing advantages over competing therapies.
You may also be interested in...
Targanta’s Oritavacin Faces Statistical Hurdle At Advisory Committee
FDA is asking the Anti-Infective Drugs Advisory Committee to review the choice confidence interval in Targanta’s studies for the antibiotic oritavancin.
Targanta’s Oritavacin Faces Statistical Hurdle At Advisory Committee
FDA is asking the Anti-Infective Drugs Advisory Committee to review the choice confidence interval in Targanta’s studies for the antibiotic oritavancin.
As Cubicin Threats Line Up, Cubist Spells Out A Strategy
Firm seeks new indications, late-stage assets.